Aspira Pathlab promoter Jay Arvind Bhanushali buys 1,424 shares
- Promoter Jay Arvind Bhanushali acquired 1,424 equity shares in open market
- Stake increases from 7.27% to 7.28% of total share capital
- Transaction period spanned September 17 to September 24, 2026
- Disclosure made under SEBI SAST Regulations 2011, Regulation 29(2)

*this image is generated using AI for illustrative purposes only.
Aspira Pathlab & Diagnostics Ltd promoter Jay Arvind Bhanushali acquired 1,424 equity shares in the open market, increasing his holding to 7.28% of the company's total share capital.
The acquisition was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction took place between September 17, 2026, and September 24, 2026. Prior to this purchase, Bhanushali held 7,47,838 shares, representing a 7.27% stake.
Transaction details
The promoter group member executed the purchase through open market transactions. The total diluted share capital of the company remains unchanged at ₹10.29 crore, divided into 1,02,93,000 equity shares of ₹10 each.
| Metric | Before Acquisition | After Acquisition |
|---|---|---|
| Number of Shares | 7,47,838 | 7,49,262 |
| Percentage Holding | 7.27% | 7.28% |
| Encumbered Shares | 0 | 0 |
The disclosure confirms that no voting rights were acquired otherwise than by shares, and no warrants or convertible securities were involved in this specific transaction. The acquirer holds no encumbrances such as pledges or liens on these shares.
Regulatory compliance
This filing serves as a mandatory disclosure for substantial acquisitions where the change in holding is less than 5% but triggers reporting requirements for promoters. The company's registered office is located in Ghatkopar (West), Mumbai. The disclosure was submitted to BSE Limited, where the scrip is listed.
Historical Stock Returns for Aspira Pathlab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.02% | +13.04% | +50.29% | +124.14% | +110.12% | 0.0% |
Will the promoter's incremental buying signal a broader accumulation trend or precede a larger stake-building campaign?
How might this minor increase in promoter holding influence retail investor sentiment and trading volume for Aspira Pathlab shares?
Are there any upcoming corporate actions or strategic announcements expected that could justify the promoter's continued market participation?






























